METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Clinical trials for METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for lung cancer patients: experimental drug trial seeks to boost standard treatment
Disease control Recruiting nowThis trial is testing whether adding an experimental drug called visugromab to standard first-line treatment helps people with newly diagnosed, advanced non-squamous lung cancer. About 107 participants will be randomly assigned to receive either the new combination or the standar…
Matched conditions: METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated Mar 23, 2026 15:28 UTC
-
Virus therapy tested to fight lung cancer that stops responding to treatment
Disease control Recruiting nowThis study is for people with advanced non-small cell lung cancer that has started to grow again after their first treatment with immunotherapy and chemotherapy. It compares a new two-part treatment—first a specially engineered virus given by IV, followed by standard chemotherapy…
Matched conditions: METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Genelux Corporation • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC
-
New antibody joins fight against tough lung cancers
Disease control Recruiting nowThis study is testing whether adding a new antibody drug called visugromab to standard treatments helps control advanced non-small cell lung cancer that has worsened after initial therapy. It will compare different combinations of visugromab, an immunotherapy drug (nivolumab), an…
Matched conditions: METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated Feb 23, 2026 14:56 UTC